1. WHO (2021), Depression factsheet:
  2. WHO (2021), Depression factsheet:
  3. WHO (2022), Mental health at work, The Lancet Global Health:
  4. Antidepressant Use Among Adults: United States, 2015-2018 (2020):
  5. STAR*DTrial: research/practical/stard/allmedicationlevels.shtml
  6. Trivedi MH., Rush AJ., Wisniewski SR., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D:  implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
  7. Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ. Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials. Int J Neuropsychopharmacol. 2015 Jul 7;19(2):pyv076. doi: 10.1093/ijnp/pyv076. Erratum in: Int J Neuropsychopharmacol. 2016 Apr 27;: PMID: 26152228; PMCID: PMC4772815.
  8. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002 Apr;36(4):578-84. doi:10.1345/aph.1A254. PMID: 11918502.
  9. Carbonaro, T. M., & Gatch, M. B. (2016). Neuropharmacology of N,N-dimethyltryptamine. Brain Research Bulletin, 126, 74–88.
  10.  Based on comparison to current antidepressant therapies available
  11. Based on current data on efficacy of psilocybin to treat TRD (see Carhart-Harris, R.L., Roseman, L., Bolstridge, M. et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep 7, 13187 (2017). and mechanistic data to suggest similar mechanism of action of DMT to psilocybin


  1. Drug Science (2022), What is DMT Therapy:
  2. Drug Science (2022), What is DMT Therapy:

About Small Pharma

We’re a biotechnology company researching and developing short-acting psychedelics with supportive therapy for mental health conditions.

Register for Company Updates

    Corporate Presentation

    Follow us: